Peregrine Ventures

Peregrine Ventures is a prominent Israeli venture capital fund, headquartered in Or Yehuda, with a dedicated focus on the life sciences sector. Established with a vision to foster groundbreaking medical innovation, the firm primarily invests in medical devices, digital health, and biotechnology companies. Their strategic approach spans cross-stage investments, allowing them to support promising ventures from early development through to commercialization. Peregrine Ventures is recognized for its deep industry expertise and hands-on approach, aiming to transform innovative concepts into market-ready solutions that address significant healthcare needs.

The firm's investment philosophy centers on identifying companies with disruptive technologies and strong intellectual property, often within the vibrant Israeli innovation ecosystem. While they engage in various stages, Peregrine Ventures frequently targets early to mid-stage companies that have demonstrated initial proof-of-concept or are approaching clinical validation. Beyond providing capital, Peregrine distinguishes itself by offering comprehensive strategic and operational support. Their team, comprising seasoned entrepreneurs, scientists, and financial experts, actively mentors portfolio companies through critical milestones such as regulatory approvals, clinical trials, and market penetration, leveraging their extensive network and industry insights.

Peregrine Ventures typically deploys initial investments ranging from $3 million to $5 million, reflecting their commitment to providing substantial early-stage support. However, their total investment per company can extend significantly, often reaching up to $15 million to $20 million through follow-on rounds, demonstrating a long-term commitment to their portfolio companies' growth. The firm has a strong fundraising track record, notably closing its fifth fund, Peregrine Ventures V, at $300 million in 2022. This substantial capital base allows them to maintain a robust investment pace and support their portfolio companies through multiple financing stages, from inception to successful exit.

Peregrine's portfolio showcases a history of successful exits and impactful innovations, including companies like Valtech Cardio, acquired by Edwards Lifesciences for $690 million, and Eximo Medical, acquired by AngioDynamics. These successes underscore their ability to identify and nurture companies that achieve significant clinical and commercial milestones. The firm's consistent focus on the life sciences has positioned it as a key player in the Israeli tech landscape, contributing significantly to the development of cutting-edge medical technologies that have a global reach and impact.